Defining the thrombotic risk in patients with myeloproliferative neoplasms

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 1131-1137

  Vianello, Fabrizio ^a   Battisti, Anna ^a   Cella, Giuseppe ^a   Marchetti, Marina ^b   Falanga, Anna ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Essential thrombocythemia; Myeloproliferative neoplasms; Nitric oxide; Polycythemia vera; Selectins; Thromboembolism; Tissue factor

Indexed keywords

CATHEPSIN G; ELASTASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; JANUS KINASE 2; L SELECTIN; NITRIC OXIDE; PADGEM PROTEIN; THROMBOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ARTERY THROMBOSIS; BLEEDING TENDENCY; BRAIN ISCHEMIA; BUDD CHIARI SYNDROME; CANCER GROWTH; CARDIOVASCULAR RISK; CELL INTERACTION; DEEP VEIN THROMBOSIS; ENDOTHELIAL DYSFUNCTION; GENE MUTATION; HUMAN; INNER CELL MASS; LEUKOCYTE; LIVER VEIN THROMBOSIS; LUNG EMBOLISM; MESENTERIC VEIN THROMBOSIS; MORBIDITY; MORTALITY; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOID METAPLASIA; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYCYTHEMIA VERA; SHORT SURVEY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTHEMIA; THROMBOSIS; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD PLATELETS; ENDOTHELIUM; HUMANS; INCIDENCE; LEUKOCYTES; MYELOPROLIFERATIVE DISORDERS; NITRIC OXIDE; POLYCYTHEMIA VERA; RISK ASSESSMENT; SELECTINS; THROMBOCYTOSIS; THROMBOSIS;

EID: 79958106601     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2011.108     Document Type: Short Survey

References (42)

1. Levine, R.L. and Gilliland, D.G. (2008) Myeloproliferative disorders. Blood 112, 2190-2198.
2. Spivak, J.L., Barosi, G., Tognoni, G., Barbui, T., Finazzi, G., Marchioli, R., and Marchetti, M. (2003) Chronic myeloproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program 200-224.
3. Michiels, J.J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U., and van Vliet, H.H. (2006) The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin. Thromb. Hemost. 32, 589-604. (Pubitemid 44453020)
4. Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood 64, 1-12.
5. Kiladjian, J.J., Cervantes, F., Leebeek, F.W., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.C., Darwish Murad, S., Raffa, S., Janssen, H.L., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P., and Valla, D.C. (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111, 4922-4929.
6. Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., and Barbui, T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J. Clin. Oncol. 23, 2224-2232. (Pubitemid 46218714)
7. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F., and Barbui, T. (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 8, 556-562. (Pubitemid 20087557)
8. Kunapuli, S.P. (2002) P2 receptors and platelet activation. TheScientificWorldJOURNAL 2, 424-433.
9. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E., and Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353, 33-45. (Pubitemid 41007805)
10. Griesshammer, M., Beneke, H., Nussbaumer, B., Grunewald, M., Bangerter, M., and Bergmann, L. (1999) Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb. Res. 96, 191-196. (Pubitemid 29531566)
11. Jensen, M.K., de Nully Brown, P., Lund, B.V., Nielsen, O.J., and Hasselbalch, H.C. (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br. J. Haematol. 110, 116-124. (Pubitemid 30625599)
12. Villmow, T., Kemkes-Matthes, B., and Matzdorff, A.C. (2002) Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb. Res. 108, 139-145. (Pubitemid 36187452)
13. Afshar-Kharghan, V., Lopez, J.A., Gray, L.A., Padilla, A., Borthakur, G., Roberts, S.C., Pruthi, R.K., and Tefferi, A. (2004) Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul. Fibrinolysis 15, 21-24. (Pubitemid 38534681)
14. Manoharan, A., Gemmell, R., Brighton, T., Dunkley, S., Lopez, K., and Kyle, P. (1999) Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br. J. Haematol. 105, 618-625. (Pubitemid 29277016)
15. Danesh, J., Collins, R., Appleby, P., and Peto, R. (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-1482. (Pubitemid 28228207)
16. Lowe, G.D., Fowkes, F.G., Dawes, J., Donnan, P.T., Lennie, S.E., and Housley, E. (1993) Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87, 1915-1920. (Pubitemid 23165634)
17. Barbui, T., Carobbio, A., Rambaldi, A., and Finazzi, G. (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114, 759-763.
18. Harlan, J.M., Killen, P.D., Harker, L.A., Striker, G.E., and Wright, D.G. (1981) Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J. Clin. Invest. 68, 1394-1403. (Pubitemid 12194392)
19. Kolpakov, V., D'Adamo, M.C., Salvatore, L., Amore, C., Mironov, A., Iacoviello, L., and Donati, M.B. (1994) Neutrophil derived cathepsin G induces potentially thrombogenic changes in human endothelial cells: a scanning electron microscopy study in static and dynamic conditions. Thromb. Haemost. 72, 140-145. (Pubitemid 24202309)
20. Falanga, A., Marchetti, M., Evangelista, V., Vignoli, A., Licini, M., Balicco, M., Manarini, S., Finazzi, G., Cerletti, C., and Barbui, T. (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96, 4261-4266.
21. Marchetti, M. and Falanga, A. (2008) Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol. Haemost. Thromb. 36, 148-159.
22. Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., Russo, L., Guerini, V., and Barbui, T. (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp. Hematol. 35, 702-711. (Pubitemid 46601748)
23. Marchetti, M., Castoldi, E., Spronk, H.M., van Oerle, R., Balducci, D., Barbui, T., Rosing, J., Ten Cate, H., and Falanga, A. (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112, 4061-4068.
24. Entman, M.L. and Ballantyne, C.M. (1996) Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy? Circulation 94, 1206-1208.
25. Michelson, A.D., Barnard, M.R., Krueger, L.A., Valeri, C.R., and Furman, M.I. (2001) Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104, 1533-1537. (Pubitemid 32917347)
26. Falanga, A., Marchetti, M., Vignoli, A., Balducci, D., and Barbui, T. (2005) Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp. Hematol. 33, 523-530. (Pubitemid 40592168)
27. Friedenberg, W.R., Roberts, R.C., and David, D.E. (1992) Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am. J. Hematol. 40, 283-289.
28. Weksler, B.B., Jaffe, E.A., Brower, M.S., and Cole, O.F. (1989) Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells. Blood 74, 1627-1634. (Pubitemid 19251539)
29. Carlos, T.M. and Harlan, J.M. (1994) Leukocyte-endothelial adhesion molecules. Blood 84, 2068-2101. (Pubitemid 24296363)
30. Karakantza, M., Giannakoulas, N.C., Zikos, P., Sakellaropoulos, G., Kouraklis, A., Aktypi, A., Metallinos, I.C., Theodori, E., Zoumbos, N.C., and Maniatis, A. (2004) Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int. J. Hematol. 79, 253-259. (Pubitemid 38620775)
31. Musolino, C., Alonci, A., Bellomo, G., Tringali, O., Spatari, G., Quartarone, C., Rizzo, V., Calabro, L., Bagnato, G., and Frisina, N. (2000) Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 4, 397-402. (Pubitemid 30098759)
32. Cella, G., Marchetti, M., Vianello, F., Panova-Noeva, M., Vignoli, A., Russo, L., Barbui, T., and Falanga, A. (2010) Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb. Haemost. 104, 151-156.
33. Freedman, J.E. and Loscalzo, J. (2003) Nitric oxide and its relationship to thrombotic disorders. J. Thromb. Haemost. 1, 1183-1188.
34. Freedman, J.E., Ting, B., Hankin, B., Loscalzo, J., Keaney, J.F., Jr., and Vita, J.A. (1998) Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 98, 1481-1486. (Pubitemid 28481663)
35. Rejto, L., Huszka, M., Kaplar, M., and Udvardy, M. (2003) Effects of in vitro platelet activation on platelet derived nitric oxide production in healthy humans and in chronic myeloproliferative diseases with elevated platelet counts. Platelets 14, 283-286. (Pubitemid 37153440)
36. Glover, R.E., Ivy, E.D., Orringer, E.P., Maeda, H., and Mason, R.P. (1999) Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol. Pharmacol. 55, 1006-1010. (Pubitemid 29252365)
37. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., and Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332, 1132-1136.
38. Shibata, J., Hasegawa, J., Siemens, H.J., Wolber, E., Dibbelt, L., Li, D., Katschinski, D.M., Fandrey, J., Jelkmann, W., Gassmann, M., Wenger, R.H., and Wagner, K.F. (2003) Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood 101, 4416-4422. (Pubitemid 36857807)
39. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., and Marchioli, R. (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109, 2446-2452. (Pubitemid 46425887)
40. Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R., and Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin. Proc. 81, 159-166. (Pubitemid 43205767)
41. De Stefano, V., Za, T., Rossi, E., Vannucchi, A.M., Ruggeri, M., Elli, E., Mico, C., Tieghi, A., Cacciola, R.R., Santoro, C., Gerli, G., Guglielmelli, P., Pieri, L., Scognamiglio, F., Rodeghiero, F., Pogliani, E.M., Finazzi, G., Gugliotta, L., Leone, G., and Barbui, T. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am. J. Hematol. 85, 97-100.
42. Girodon, F., Dutrillaux, F., Broseus, J., Mounier, M., Goussot, V., Bardonnaud, P., Chretien, M.L., and Maynadie, M. (2010) Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia 24, 900-903.